[en] Generation and deposition of amyloid beta peptides and neurofibrillary tangle formation are key mechanisms involved in AD pathogenesis. Recent evidence suggests that inflammatory mechanisms represent a third component which, once initiated by degeneration, may significantly contribute to disease progression and chronicity. Various neuroinflammatory mediators including complement activators and inhibitors, chemokines, cytokines, radical oxygen species and inflammatory enzymes are generated and released by microglia, astrocytes and neurons. Degeneration of aminergic brain stem nuclei such as the locus ceruleus and the nucleus baslis of Meynert may facilitate the occurrence of inflammation in their respective projection areas given the antiinflammatory and neuroprotective action of their key products norepinephrine and acetylcholine. While inflammation has been thought to arise secondary to degeneration, recent experiments demonstrated that inflammatory mediators may stimulate APP processing by upregulation of beta secretase 1 and therefore are able to establish a vicious cycle. Despite the fact that some aspects of inflammation may even exert protective effects to bystander neurons, antiinflammatory treatment strategies should therefore be considered. Non-steroidal antiinflammatory drugs have been shown to reduce the risk and delay the onset to develop AD. However, the precise molecular mechanism underlying this effect is still being debated. Several mechanisms including inhibition of cyclooxygenase 2, gamma secretase or activation of the peroxisome proliferator activated receptor gamma may alone or, more likely, in concert account for the epidemiologically observed protection.
Disciplines :
Neurology
Author, co-author :
HENEKA, Michael ; Department of Neurology, Molecular Neurology Unit, University of Münster, Mendelstrasse 7, D-48149, Münster, Germany. heneka@uni-muenster.de
O'Banion, M Kerry; Department of Neurology, Molecular Neurology Unit, University of Münster, D-48149 Münster, Germany ; Departments of Neurobiology and Anatomy and of Neurology, University of Rochester, Rochester, NY, United States
Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., and Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. J. Neuroimmunol. 126 (2002) 50-57
Adolfsson R., Gottfries C.G., Roos B.E., and Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 135 (1979) 216-223
Agdeppa E.D., Kepe V., Petri A., Satyamurthy N., Liu J., Huang S.C., Small G.W., Cole G.M., and Barrio J.R. In vitro detection of S-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-1-[6-[2-[18F]fluoroethylmethylamino]-2-naphthyl]ethylidenemalono nitrile. Neuroscience 117 (2003) 723-730
Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., and Thal L.J. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
Alafuzoff I., Overmyer M., Helisalmi S., and Soininen H. Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs. J. Alzheimer's Dis. 2 (2000) 37-46
Almer G., Vukosavic S., Romero N., and Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72 (1999) 2415-2425
Aloisi F., Care A., Borsellino G., Gallo P., Rosa S., Bassani A., Cabibbo A., Testa U., Levi G., and Peschle C. Production of hemolymphopoietic cytokines Il-6, Il-8, colony-stimulating factors by normal human astrocytes in response to Il-1-beta and tumor-necrosis-factor-alpha. J. Immunol. 149 (1992) 2358-2366
Amara F.M., Junaid A., Clough R.R., and Liang B.H. TGF-beta1, regulation of Alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization. Mol. Brain Res. 71 (1999) 42-49
Anthony J.C., Breitner J.C., Zandi P.P., Meyer M.R., Jurasova I., Norton M.C., and Stone S.V. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54 (2000) 2066-2071
Apelt R., and Schliebs J. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 894 (2001) 21-30
Bach J.H., Chae H.S., Rah J.C., Lee M.W., Park C.H., Choi S.H., Choi J.K., Lee S.H., Kim Y.S., Kim K.Y., Lee W.B., Suh Y.H., and Kim S.S. C-terminal fragment of amyloid precursor protein induces astrocytosis. J. Neurochem. 78 (2001) 109-120
Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585-595
Barger S.W., and Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388 (1997) 878-881
Barger S.W., Smithswintosky V.L., Rydel R.E., and Mattson M.P. Beta-amyloid precursor protein mismetabolism and loss of calcium homeostasis in Alzheimers-disease. Alzheimers Dis.: Amyloid Precursor Proteins Signal Transduct. Neuronal Transplant. 695 (1993) 158-164
Barger S.W., Horster D., Furukawa K., Goodman Y., Krieglstein J., and Mattson M.P. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9328-9332
Bate C., Veerhuis R., Eikelenboom P., and Williarns A. Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport 15 (2004) 1427-1430
Bauer M.K., Lieb K., Schulze-Osthoff K., Berger M., Gebicke-Haerter P.J., Bauer J., and Fiebich B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 243 (1997) 726-731
Beard C.M., Waring S.C., O'Brien P.C., Kurland L.T., and Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin. Proc. 73 (1998) 951-955
Beglopoulos V., Sun X., Saura C.A., Lemere C.A., Kim R.D., and Shen J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J. Biol. Chem. 279 (2004) 46907-46914
Benveniste E.N., Nguyen V.T., and O'Keefe G.M. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem. Int. 39 (2001) 381-391
Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., and Brunden K.R. Evidence for glial-mediated inflammation in aged APPSW transgenic mice. Neurobiol. Aging 20 (1999) 581-589
Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., Vescovi A., Bagetta G., Kollias G., Meldolesi J., and Volterra A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 4 (2001) 702-710
Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., and Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56 (2004) 240-248
Blasko I., Marx F., Steiner E., Hartmann T., and Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 13 (1999) 63-68
Blasko I., Veerhuis R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P., and Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol. Dis. 7 (2000) 682-689
Blasko I., Apochal A., Boeck G., Hartmann T., Grubeck-Loebenstein B., and Ransmayr G. Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol. Dis. 8 (2001) 1094-1101
Blasko I., Beer R., Bigl M., Apelt J., Franz G., Rudzki D., Ransmayr G., Kampfl A., and Schliebs R. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase BACE-1. J. Neural Transm. 111 (2004) 523-536
Boje K.M., and Arora P.K. Microglial-produced nitric-oxide and reactive nitrogen-oxides mediate neuronal cell-death. Brain Res. 587 (1992) 250-256
Bondareff W., Mountjoy C.Q., Roth M., Rossor M.N., Iversen L.L., Reynolds G.P., and Hauser D.L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1 (1987) 256-262
Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., Wang H., Abumrad N., Eaton J.W., and Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-462
Botchkina G.I., Meistrell III M.E., Botchkina I.L., and Tracey K.J. Expression of TNF and TNF receptors p55 and p75 in the rat brain after focal cerebral ischemia. Mol. Med. 3 (1997) 765-781
Botto M. C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp. Clin. Immunogenet. 15 (1998) 231-234
Braak H., and Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm., Suppl. 53 (1998) 127-140
Braida D., Sacerdote P., Panerai A.E., Bianchi M., Aloisi A.M., Iosue S., and Sala M. Cognitive function in young and adult IL interleukin-6 deficient mice. Behav. Brain Res. 153 (2004) 423-429
Breder C.D., Tsujimoto M., Terano Y., Scott D.W., and Saper C.B. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J. Comp. Neurol. 337 (1993) 543-567
Bredt D.S., and Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 682-685
Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
Breitner J.C. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol. Aging 17 (1996) 789-794
Breitner J.C., and Zandi P.P. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?. N. Engl. J. Med. 345 (2001) 1567-1568
Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., and Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16 (1995) 523-530
Brown G.C., and Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27 (2003) 325-355
Brunkan A.L., and Goate A.M. Presenilin function and gamma-secretase activity. J. Neurochem. 93 (2005) 769-792
Butovsky O., Talpalar A.E., Ben Yaakov K., and Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell. Neurosci. 29 (2005) 381-393
Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., and Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M., Alvarez D., Al Dalain S., Martinez G., Leon O.S., and Springer J.E. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem. 86 (2003) 545-555
Castell J.V., Andus T., Kunz D., and Heinrich P.C. Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann. N. Y. Acad. Sci. 557 (1989) 87-99 discussion 100-1, 87-99
Chao C.C., Hu S., Sheng W.S., Bu D., Bukrinsky M.I., and Peterson P.K. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 16 (1996) 276-284
Charo I.F., and Ransohoff R.M. Mechanisms of disease-the many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48-52
Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 61 (1997) 2323-2333
Ciesielski-Treska J., Ulrich G., Aunis D., and Bader M.F. Chromogranin A triggers the expression of neurotoxic phenotype in microglia and induces apoptosis in neuronal/microglial cocultures. Eur. J. Neurosci. 10 (1998) 164
Ciesielski-Treska J., Ulrich G., Taupenot L., Chasserot-Golaz S., Corti A., Aunis D., and Bader M.F. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J. Biol. Chem. 273 (1998) 14339-14346
Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20 (2000) 558-567
Combs C.K., Karlo J.C., Kao S.C., and Landreth G.E. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21 (2001) 1179-1188
Conde J.R., and Streit W.J. Microglia in the aging brain. J. Neuropathol. Exp. Neurol. 65 (2006) 199-203
Corradin S.B., Mauel J., Donini S.D., Quattrocchi E., and Ricciardi-Castagnoli P. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 7 (1993) 255-262
Cunard R., Eto Y., Muljadi J.T., Glass C.K., Kelly C.J., and Ricote M. Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J. Immunol. 172 (2004) 7530-7536
D'Andrea M.R., Cole G.M., and Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25 (2004) 675-683
Davis S., and Laroche S. What can rodent models tell us about cognitive decline in Alzheimer's disease?. Mol. Neurobiol. 27 (2003) 249-276
Dawson V.L., Brahmbhatt H.P., Mong J.A., and Dawson T.M. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 33 (1994) 1425-1430
Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev., Immunol. 2 (2002) 748-759
DeGiorgio L.A., Shimizu Y., Chun H.S., Cho B.P., Sugama S., Joh T.H., and Volpe B.T. APP knockout attenuates microglial activation and enhances neuron survival in substantia nigra compacta after axotomy. Glia 38 (2002) 174-178
Dehmer T., Heneka M.T., Sastre M., Dichgans J., and Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004) 494-501
del Zoppo G., Ginis I., Hallenbeck J.M., Iadecola C., Wang X., and Feuerstein G.Z. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10 (2000) 95-112
Demerle-Pallardy C., Lonchampt M.O., Chabrier P.E., and Braquet P. Nitric oxide synthase induction in glial cells: effect on neuronal survival. Life Sci. 52 (1993) 1883-1890
Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508-2515
Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., and Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7 (1993) 75-83
Du Y.S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., and Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5296-5301
Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B.A., and Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
Eikelenboom P., and van Gool W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural Transm. 111 (2004) 281-294
Eikelenboom P., and Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17 (1996) 673-680
Eikelenboom P., Zhan S.S., van Gool W.A., and Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15 (1994) 447-450
Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., and Golde T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112 (2003) 440-449
Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 19 327 (2003) 128
Fassbender K., Walter S., Kuhl S., Landmann R., Ishii K., Bertsch T., Stalder A.K., Muehlhauser F., Liu Y., Ulmer A.J., Rivest S., Lentschat A., Gulbins E., Jucker M., Staufenbiel M., Brechtel K., Walter J., Multhaup G., Penke B., Adachi Y., Hartmann T., and Beyreuther K. The LPS receptor CD14 links innate immunity with Alzheimer's disease. FASEB J. 17 (2003)
Feinstein D.L., Heneka M.T., Gavrilyuk V., Dello R.C., Weinberg G., and Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 41 (2002) 357-365
Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., and Russo C.D. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 70 (2005) 177-188
Fetler L., and Amigorena S. Neuroscience. Brain under surveillance: the microglia patrol. Science 309 (2005) 392-393
Feuerstein G.Z., Liu T., and Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev. 6 (1994) 341-360
Fiebich B.L., Schleicher S., Spleiss O., Czygan M., and Hull M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem. 79 (2001) 950-958
Fishel M.A., Watson G.S., Montine T.J., Wang Q., Green P.S., Kulstad J.J., Cook D.G., Peskind E.R., Baker L.D., Goldgaber D., Nie W., Asthana S., Plymate S.R., Schwartz M.W., and Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults. Arch. Neurol. 62 (2005) 1539-1544
Floden A.M., and Combs C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J. Neurosci. 26 (2006) 4644-4648
Fonseca M.I., Zhou J., Botto M., and Tenner A.J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24 (2004) 6457-6465
Forno L.S. Pathology of Parkinsonism. J. Neurosurg. (1966) 266-271
Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., and Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152 (1998) 307-317
Freedman R., Foote S.L., and Bloom F.E. Histochemical characterization of a neocortical projection of the nucleus locus coeruleus in the squirrel monkey. J. Comp. Neurol. 164 (1975) 209-231
Frei K., Nohava K., Malipiero U.V., Schwerdel C., and Fontana A. Production of macrophage colony-stimulating factor by astrocytes and brain macrophages. J. Neuroimmunol. 40 (1992) 189-196
Fritschy J.M., and Grzanna R. Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30 (1989) 181-197
Galea E., Feinstein D.L., and Reis D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10945-10949
Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
Gasque P., Fontaine M., and Morgan B.P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154 (1995) 4726-4733
Gavrilyuk V., Dello R.C., Heneka M.T., Pelligrino D., Weinberg G., and Feinstein D.L. Norepinephrine increases I kappa B alpha expression in astrocytes. J. Biol. Chem. 277 (2002) 29662-29668
German D.C., Manaye K.F., White III C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., and Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 (1992) 667-676
Glabinski A.R., and Ransohoff R.M. Chemokines and chemokine receptors in CNS pathology. J. Neurovirology 5 (1999) 3-12
Gong C., Qin Z., Betz A.L., Liu X.H., and Yang G.Y. Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice. Brain Res. 801 (1998) 1-8
Graham A.J., Ray M.A., Perry E.K., Jaros E., Perry R.H., Volsen S.G., Bose S., Evans N., Lindstrom J., and Court J.A. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J. Chem. Neuroanat. 25 (2003) 97-113
Grammas P., and Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 22 (2001) 837-842
Griffin W.S.T. IL-1 and the cytokine cycle in Alzheimer's disease. J. Neurochem. 74 (2000) S52
Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., and Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8 (1998) 65-72
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D.C., Mesulam, M.M., in press. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging. (Mar 27, Electronic publication ahead of print. doi:10.1016/j.neurobiolaging.2006.02.007).
Guo J.T., Yu J., Grass D., de Beer F.C., and Kindy M.S. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J. Neurosci. 22 (2002) 5900-5909
Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
Hanisch U.K. Microglia as a source and target of cytokines. Glia 40 (2002) 140-155
Hardy J., and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12 (1991) 383-388
Hartlage-Rubsamen M., Zeitschel U., Apelt J., Gartner U., Franke H., Stahl T., Gunther A., Schliebs R., Penkowa M., Bigl V., and Rossner S. Astrocytic expression of the Alzheimer's disease beta-secretase BACE1 is stimulus-dependent. Glia 41 (2003) 169-179
Heneka M.T., and Feinstein D.L. Expression and function of inducible nitric oxide synthase in neurons. J. Neuroimmunol. 114 (2001) 8-18
Heneka M.T., Loschmann P.A., Gleichmann M., Weller M., Schulz J.B., Wullner U., and Klockgether T. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J. Neurochem. 71 (1998) 88-94
Heneka M.T., Feinstein D.L., Galea E., Gleichmann M., Wullner U., and Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156-168
Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20 (2000) 6862-6867
Heneka M.T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D.L., and Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 906-916
Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., and Feinstein D.L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22 (2002) 2434-2442
Heneka M.T., Gavrilyuk V., Landreth G.E., O'Banion M.K., Weinberg G., and Feinstein D.L. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J. Neurochem. 85 (2003) 387-398
Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Dewachter I., Walter J., Klockgether T., and Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflam. 2 (2005) 22
Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., and Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T., and Staufenbiel M. Locus Ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26 (2006) 1343-1354
Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., and Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free-radical generation by the peptide - relevance to Alzheimer-disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3270-3274
Hesselgesser J., and Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J. Neurovirology 5 (1999) 13-26
Hewett S.J., Csernansky C.A., and Choi D.W. Selective potentiation of NMDA-induced neuronal injury following induction of astrocytic iNOS. Neuron 13 (1994) 487-494
Heyser C.J., Masliah E., Samimi A., Campbell I.L., and Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1500-1505
Ho L., Purohit D., Haroutunian V., Luterman J.D., Willis F., Naslund J., Buxbaum J.D., Mohs R.C., Aisen P.S., and Pasinetti G.M. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 58 (2001) 487-492
Ho G.J., Drego R., Hakimian E., and Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy 4 (2005) 247-256
Hoozemans J.J.M., Rozemuller A.J.M., Janssen I., De Groot C.J.A., Veerhuis R., and Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101 (2001) 2-8
Hoozemans J., Veerhuis R., Rozemuller A., Arendt T., and Eikelenboom P. Neuronal immunoreactivity for COX-2 and phosphorylation of prb precede P38 MAPK activation and neurofibrillary changes in ad temporal cortex. Neurobiol. Aging 25 (2004) S416
Hori K., Burd P.R., Furuke K., Kutza J., Weih K.A., and Clouse K.A. Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide NO production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Blood 93 (1999) 1843-1850
Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15 (1995) 1203-1218
Hu J.G., Akama K.T., Krafft G.A., Chromy B.A., and Van Eldik L.J. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785 (1998) 195-206
In t'Veld, Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., and Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515-1521
Ishizuka K., Kimura T., Igata-yi R., Katsuragi S., Takamatsu J., and Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51 (1997) 135-138
Itagaki S., McGeer P.L., Akiyama H., Zhu S., and Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer-disease. J. Neuroimmunol. 24 (1989) 173-182
Iversen L.L., Rossor M.N., Reynolds G.P., Hills R., Roth M., Mountjoy C.Q., Foote S.L., Morrison J.H., and Bloom F.E. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci. Lett. 19 39 (1983) 95-100
Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
Kalaria R.N., Andorn A.C., Tabaton M., Whitehouse P.J., Harik S.I., and Unnerstall J.R. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem. 53 (1989) 1772-1781
Kamboh M.I., Sanghera D.K., Ferrell R.E., and DeKosky S.T. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet. 10 (1995) 486-488
Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S.H., Orio M., and Iadecola C. Prostaglandin E-2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 12 (2006) 225-229
Kelley K.A., Ho L., Winger D., Freire-Moar J., Borelli C.B., Aisen P.S., and Pasinetti G.M. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol. 155 (1999) 995-1004
Kelly D., Campbell J.I., King T.P., Grant G., Jansson E.A., Coutts A.G., Pettersson S., and Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5 (2004) 104-112
Kim S.U., Nagai A., Nakagawa E., Hatori K., Choi H.B., and Lee M.A. Beta-amyloid up-regulates expression of cytokines and chemokines in human microglia and human microglia cell line. J. Neuropathol. Exp. Neurol. 60 (2001) 546
Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., and Taniguchi T. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254 (1999) 582-586
Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., and Laferla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005) 8843-8853
Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., and Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 19;91 (1994) 7355-7359
Koistinaho M., Lin S.Z., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., and Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10 (2004) 719-726
Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996) 312-318
Lamb B.T., Bardel K.A., Kulnane L.S., Anderson J.J., Holtz G., Wagner S.L., Sisodia S.S., and Hoeger E.J. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat. Neurosci. 2 (1999) 695-697
Landreth G.E., and Heneka M.T. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging 22 (2001) 937-944
Lee S.C., Collins M., Vanguri P., and Shin M.L. Glutamate differentially inhibits the expression of class II MHC antigens on astrocytes and microglia. J. Immunol. 148 (1992) 3391-3397
Lee S.C., Zhao M.L., Hirano A., and Dickson D.W. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J. Neuropathol. Exp. Neurol. 58 (1999) 1163-1169
Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
Lee Y.B., Nagai A., and Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 69 (2002) 94-103
Lee E.O., Shin Y.J., and Chong Y.H. Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. J. Neuroimmunol. 155 (2004) 21-31
Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
Li M., Pascual G., and Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20 (2000) 4699-4707
Li Y.K., Liu L., Barger S.W., and Griffin W.S.T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23 (2003) 1605-1611
Liang X.B., Wang Q., Hand T., Wu L.J., Breyer R.M., Montine T.J., and Andreasson K. Deletion of the prostaglandin E-2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25 (2005) 10180-10187
Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., and Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000) 5709-5714
Lim G.P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., Overmier J.B., Hsiao-Ashec K., Frautschy S.A., and Cole G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22 (2001) 983-991
Lindberg C., Selenica M.L.B., Westlind-Danielsson A., and Schultzberg M. beta-amyloid protein structure determines the nature of cytokine release from rat microglia. J. Mol. Neurosci. 27 (2005) 1-12
Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304 (2003) 1-7
Lleo A., Berezovska O., Herl L., Raju S., Deng A., Bacskai B.J., Frosch M.P., Irizarry M., and Hyman B.T. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 10 (2004) 1065-1066
Lue L.F., Rydel R., Brigham E.F., Yang L.B., Hampel H., Murphy G.M., Brachova L., Yan S.D., Walker D.G., Shen Y., and Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35 (2001) 72-79
Lue L.F., Walker D.G., and Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging 22 (2001) 945-956
Lukiw W.J., and Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50 (1997) 937-945
Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
Ma J.Y., Yee A., Brewer H.B., Das S., and Potter H. Amyloid-associated proteins alpha1-antichymotrypsin and apolipoprotein-e promote assembly of Alzheimer beta-protein into filaments. Nature 372 (1994) 92-94
Mackenzie I.R. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol. Aging 22 (2001) 819-822
Mackenzie I.R., and Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50 (1998) 986-990
Magnuson D.S., Staines W.A., and Marshall K.C. Electrophysiological changes accompanying DSP-4 lesions of rat locus coeruleus neurons. Brain Res. 19 628 (1993) 317-320
Mann D.M., Lincoln J., Yates P.O., Stamp J.E., and Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry 136 (1980) 533-541
Mann D.M., Yates P.O., and Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry 45 (1982) 113-119
Marcyniuk B., Mann D.M., and Yates P.O. The topography of cell loss from locus caeruleus in Alzheimer's disease. J. Neurol. Sci. 76 (1986) 335-345
Marien M.R., Colpaert F.C., and Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain. Res. Brain Res. Rev. 45 (2004) 38-78
Mattson M.P. ways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., and Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41 (1991) 507-523
McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., and Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24 (2004) 257-268
McCusker S.M., Curran M.D., Dynan K.B., McCullagh C.D., Urquhart D.D., Middleton D., Patterson C.C., McIlroy S.P., and Passmore A.P. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357 (2001) 436-439
McGeer P.L., and McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain. Res. Brain Res. Rev. 21 (1995) 195-218
McGeer P.L., and McGeer E.G. The possible role of complement activation in Alzheimer disease. Trends Mol. Med. 8 (2002) 519-523
McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
Mehlhorn G., Hollborn M., and Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18 (2000) 423-431
Minghetti L., Polazzi E., Nicolini A., Creminon C., and Levi G. Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur. J. Neurosci. 9 (1997) 934-940
Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., Godaux E., Cordell B., and Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274 (1999) 6483-6492
Moncada C., Lekieffre D., Arvin B., and Meldrum B. Effect of NO synthase inhibition on NMDA- and ischaemia-induced hippocampal lesions. Neuroreport 3 (1992) 530-532
Montine T.J., Sidell K.R., Crews B.C., Markesbery W.R., Marnett L.J., Roberts L.J., and Morrow J.D. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53 (1999) 1495-1498
Moore A.H., Olschowka J.A., Williams J.P., Okunieff P., and O'Banion M.K. Regulation of prostaglandin E-2 synthesis after brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 267-272
Mori K., Togashi H., Ueno K., Matsumoto M., and Yoshioka M. Aminoguanidine prevented the impairment of learning behavior and hippocampal long-term potentiation following transient cerebral ischemia. Behav. Brain Res. 120 (2001) 159-168
Morihara T., Teter B., Yang F., Lim G.P., Boudinot S., Boudinot F.D., Frautschy S.A., and Cole G.M. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid Abeta pathology in Alzheimer's models. Neuropsychopharmacology 30 (2005) 1111-1120
Morimoto K., Murasugi T., and Oda T. Acute neuroinflammation exacerbates excitotoxicity in rat hippocampus in vivo. Exp. Neurol. 177 (2002) 95-104
Mrak R.E., and Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging 22 (2001) 903-908
Murphy P.G., Borthwick L.S., Johnston R.S., Kuchel G., and Richardson P.M. Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons. J. Neurosci. 19 (1999) 3791-3800
Murray C.A., and Lynch M.A. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J. Neurosci. 18 (1998) 2974-2981
Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: Role for cytokines. Curr. Pharm. Des. 11 (2005) 999-1016
Nagele R.G., D'Andrea M.R., Lee H., Venkataraman V., and Wang H.Y. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 971 (2003) 197-209
Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
Natarajan C., and Bright J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 3 (2002) 59-70
Nicoll J.A., Mrak R.E., Graham D.I., Stewart J., Wilcock G., MacGowan S., Esiri M.M., Murray L.S., Dewar D., Love S., Moss T., and Griffin W.S. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47 (2000) 365-368
Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
Nishino K., Lin C.S., Morse J.K., and Davis J.N. DSP4 treatment worsens hippocampal pyramidal cell damage after transient ischemia. Neuroscience 43 (1991) 361-367
Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
O'Banion M.K., Miller J.C., Chang J.W., Kaplan M.D., and Coleman P.D. Interleukin-1 beta induces prostaglandin G/H synthase-2 cyclooxygenase-2 in primary murine astrocyte cultures. J. Neurochem. 66 (1996) 2532-2540
O'Banion M.K., Chang J.W., and Coleman P.D. Decreased expression of prostaglandin G/H synthase-2 PGHS-2 in Alzheimer's disease brain. Adv. Exp. Med. Biol. 407 (1997) 171-177
Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and Laferla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A beta and synaptic dysfunction. Neuron 39 (2003) 409-421
Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., and Laferla F.M. Temporal profile of amyloid-beta A beta oligomerization in an in vivo model of Alzheimer disease - a link between A beta and tau pathology. J. Biol. Chem. 281 (2006) 1599-1604
Oka A., and Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8 (1997) 1161-1164
Olpe H.R., Laszlo J., Dooley D.J., Heid J., and Steinmann M.W. Decreased activity of locus coeruleus neurons in the rat after DSP-4 treatment. Neurosci. Lett. 40 (1983) 81-84
Orzylowska O., Oderfeld-Nowak B., Zaremba M., Januszewski S., and Mossakowski M. Prolonged and concomitant induction of astroglial immunoreactivity of interleukin-1beta and interleukin-6 in the rat hippocampus after transient global ischemia. Neurosci. Lett. 263 (1999) 72-76
Osaka H., Mukherjee P., Aisen P.S., and Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell. Biochem. 73 (1999) 303-311
Owens T., Babcock A.A., Millward J.M., and Toft-Hansen H. Cytokine and chemokine inter-regulation in the inflamed or injured CNS. Brain Res. Brain Res. Rev. 48 (2005) 178-184
Papassotiropoulos A., Bagli M., Jessen F., Bayer T.A., Maier W., Rao M.L., and Heun R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45 (1999) 666-668
Paresce D.M., Ghosh R.N., and Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17 (1996) 553-565
Pasinetti G.M., Tocco G., Sakhi S., Musleh W.D., DeSimoni M.G., Mascarucci P., Schreiber S., Baudry M., and Finch C.E. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol. Dis. 3 (1996) 197-204
Patsouris D., Muller M., and Kersten S. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Curr. Opin. Investig. Drugs 5 (2004) 1045-1050
Pavlov V.A., and Tracey K.J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 19 (2005) 493-499
Perry R.T., Collins J.S., Harrell L.E., Acton R.T., and Go R.C. Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am. J. Med. Genet. 105 (2001) 332-342
Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., and Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11294-11298
Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
Rangon C.M., Haik S., Faucheux B.A., Metz-Boutigue M.H., Fierville F., Fuchs J.P., Hauw J.J., and Aunis D. Different chromogranin immunoreactivity between prion and a-beta amyloid plaque. Neuroreport 14 (2003) 755-758
Ray I., Chauhan A., Wisniewski H.M., Wegiel J., Kim K.S., and Chauhan V.P. Binding of amyloid beta-protein to intracellular brain proteins in rat and human. Neurochem. Res. 23 (1998) 1277-1282
Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., Norman B.A., and Baranak C.C. Rofecoxib - no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., and Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45 (1995) 51-55
Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 82 (2004) 510-529
Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., and Lieberburg I. Complement activation by beta-amyloid in Alzheimer-disease. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10016-10020
Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43 (1993) 1609-1611
Rogers J.T., Leiter L.M., McPhee J., Cahill C.M., Zhan S.S., Potter H., and Nilsson L.N. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J. Biol. Chem. 274 (1999) 6421-6431
Rossi F., and Bianchini E. Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem. Biophys. Res. Commun. 225 (1996) 474-478
Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappa B kinase. Nature 403 (2000) 103-108
Rossner S., Lange-Dohna C., Zeitschel U., and Perez-Polo J.R. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem. 92 (2005) 226-234
Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., and Ferrero P. Increased intrathecal TGF-beta 1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27 (2006) 33-39
Rozemuller J.M., Eikelenboom P., Pals S.T., and Stam F.C. Microglial cells around amyloid plaques in Alzheimers-disease express leukocyte adhesion molecules of the Lfa-1 family. Neurosci. Lett. 101 (1989) 288-292
Rozemuller J.M., Eikelenboom P., Stam F.C., Beyreuther K., and Masters C.L. A4-protein in Alzheimers-disease - primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol. 48 (1989) 674-691
Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., Van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003) 9796-9804
Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., Van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 443-448
Schubert P., Morino T., Miyazaki H., Ogata T., Nakamura Y., Marchini C., and Ferroni S. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. N. Y. Acad. Sci. 903 (2000) 24-33
Selkoe D.J. Toward a remembrance of things past: deciphering Alzheimer disease. Harvey Lect. 99 (2003) 23-45
Selmaj K.W., Farooq M., Norton W.T., Raine C.S., and Brosnan C.F. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol. 144 (1990) 129-135
Semmler A., Okulla T., Sastre M., Dumitrescu-Ozimek L., and Heneka M.T. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J. Chem. Neuroanat. 30 (2005) 144-157
Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
Shen Y., and Meri S. Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 70 (2003) 463-472
Sheng J.G., Zhu S.G., Jones R.A., Griffin W.S.T., and Mrak R.E. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. 163 (2000) 388-391
Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., and Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 14 (2003) 133-145
Shie F.S., Breyer R.M., and Montine T.J. Microglia lacking E prostanoid receptor subtype 2 have enhanced abeta phagocytosis yet lack abeta-activated neurotoxicity. Am. J. Pathol. 166 (2005) 1163-1172
Shie F.S., Montine K.S., Breyer R.M., and Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52 (2005) 70-77
Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 (1992) 126-129
Simard A.R., Soulet D., Gowing G., Julien J.P., and Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49 (2006) 489-502
Simmons M.L., and Murphy S. Induction of nitric oxide synthase in glial cells. J. Neurochem. 59 (1992) 897-905
Skaper S.D., Facci L., and Leon A. Inflammatory mediator stimulation of astrocytes and meningeal fibroblasts induces neuronal degeneration via the nitridergic pathway. J. Neurochem. 64 (1995) 266-276
Slawik H., Volk B., Fiebich B., and Hull M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem. Int. 45 (2004) 653-660
Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley D.D., Carter D.B., and Chin J.E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 56 (2001) 581-588
Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
Smithswintosky V.L., Pettigrew L.C., Craddock S.D., Culwell A.R., Rydel R.E., and Mattson M.P. Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J. Neurochem. 63 (1994) 781-784
Smits H.A., Rijsmus A., van Loon J.H., Wat J.W.Y., Verhoef J., Boven L.A., and Nottet H.S.L.M. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127 (2002) 160-168
Snyder S.W., Wang G.T., Barrett L., Ladror U.S., Casuto D., Lee C.M., Krafft G.A., Holzman R.B., and Holzman T.F. Complement C1Q does not bind monomeric beta-amyloid. Exp. Neurol. 128 (1994) 136-142
Stalder A.K., Carson M.J., Pagenstecher A., Asensio V.C., Kincaid C., Benedict M., Powell H.C., Masliah E., and Campbell I.L. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient SCID mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 153 (1998) 767-783
Stalder A.K., Ermini F., Bondolfi L., Krenger W., Burbach G.J., Deller T., Coomaraswamy J., Staufenbiel M., Landmann R., and Jucker M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25 (2005) 11125-11132
Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
Streit W.J., Conde J.R., Fendrick S.E., Flanary B.E., and Mariani C.L. Role of microglia in the central nervous system's immune response. Neurol. Res. 27 (2005) 685-691
Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., Dzuiba J., Van Damme J., Walz A., Marriott D., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270 (1995) 27348-27357
Stuehr D.J., and Marletta M.A. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 7738-7742
Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13287-13292
Sung S., Yang H., Uryu K., Lee E.B., Zhao L., Shineman D., Trojanowski J.Q., Lee V.M., and Pratico D. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 165 (2004) 2197-2206
Suzuki S., Tanaka K., Nagata E., Ito D., Dembo T., and Fukuuchi Y. Cerebral neurons express interleukin-6 after transient forebrain ischemia in gerbils. Neurosci. Lett. 262 (1999) 117-120
Szczepanik A.M., Funes S., Petko W., and Ringheim G.E. IL-4, IL-10 and IL-13 modulate A beta1-42-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 113 (2001) 49-62
Szczepanik A.M., Rampe D., and Ringheim G.E. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. 77 (2001) 304-317
Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., and Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 (2004) 159-169
Takadera T., Shiraishi Y., and Ohyashiki T. Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem. Int. 45 (2004) 713-719
Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., and Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 10 (2002) 279-288
Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., and Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286 (1999) 2352-2355
Tancredi V., D'Arcangelo G., Grassi F., Tarroni P., Palmieri G., Santoni A., and Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 146 (1992) 176-178
Tancredi V., D'Antuono M., Cafe C., Giovedi S., Bue M.C., D'Arcangelo G., Onofri F., and Benfenati F. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J. Neurochem. 75 (2000) 634-643
Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
Taupenot L., CiesielskiTreska J., Ulrich G., ChasserotGolaz S., Aunis D., and Bader M.F. Chromogranin a triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 72 (1996) 377-389
Taylor P.R., Carugati A., Fadok V.A., Cook H.T., Andrews M., Carroll M.C., Savill J.S., Henson P.M., Botto M., and Walport M.J. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192 (2000) 359-366
Tchelingerian J.L., Vignais L., and Jacque C. TNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport 5 (1994) 585-588
Teaktong T., Graham A., Court J., Perry R., Jaros E., Johnson M., Hall R., and Perry E. Alzheimer's disease is associated with a selective increase in alpha 7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41 (2003) 207-211
Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., Assaid C., Nessly M.L., Norman B.A., Baranak C.C., and Reines S.A. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
Thery C., Stanley E.R., and Mallat M. Interleukin-1 and tumor-necrosis-factor-alpha stimulate the production of colony-stimulating factor-I by murine astrocytes. J. Neurochem. 59 (1992) 1183-1186
Thiemermann C. The role of the l-arginine: nitric oxide pathway in circulatory shock. Adv. Pharmacol. 28 (1994) 45-79
Thomas T., Nadackal T.G., and Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12 (2001) 3263-3267
Tocco G., Freire-Moar J., Schreiber S.S., Sakhi S.H., Aisen P.S., and Pasinetti G.M. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. 144 (1997) 339-349
Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., and Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11 (1992) 433-439
Tuppo E.E., and Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37 (2005) 289-305
Vamecq J., and Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 354 (1999) 141-148
van Beek J., Elward K., and Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. N. Y. Acad. Sci. 992 (2003) 56-71
Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den H.C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., and Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 157 (2000) 1283-1298
Veerhuis R., Boshuizen R.S., Morbin M., Mazzoleni G., Hoozemans J.J.M., Langedijk J.P.M., Tagliavini F., Langeveld J.P.M., and Eikelenboom P. Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiol. Dis. 19 (2005) 273-282
Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., Weidner J., Mumford R., Webber R., Nathan C., Roberts A.B., Lippa C.F., and Sporn M.B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184 (1996) 1425-1433
Wallace M.N., Geddes J.G., Farquhar D.A., and Masson M.R. Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp. Neurol. 144 (1997) 266-272
Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
Walter J., Fluhrer R., Hartung B., Willem M., Kaether C., Capell A., Lammich S., Multhaup G., and Haass C. Phosphorylation regulates intracellular trafficking of beta-secretase. J. Biol. Chem. 276 (2001) 14634-14641
Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H.C., Yang H., Ulloa L., Al Abed Y., Czura C.J., and Tracey K.J. Nicotinic acetylcholine receptor alpha 7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
Wang Q., Rowan M.J., and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24 (2004) 6049-6056
Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., and Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18 (1997) 415-421
Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., and Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Esler W.P., Maggio J.E., and Mantyh P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18 (1998) 2161-2173
Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., and Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22 (2002) 1858-1867
White J.A., Manelli A.M., Holmberg K.H., Van Eldik L.J., and Ladu M.J. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18 (2005) 459-465
Wilcock G.K., Esiri M.M., Bowen D.M., and Hughes A.O. The differential involvement of subcortical nuclei in senile dementia of Alzheimer's type. J. Neurol. Neurosurg. Psychiatry 51 (1988) 842-849
Willenborg D.O., Fordham S.A., Staykova M.A., Ramshaw I.A., and Cowden W.B. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 163 (1999) 5278-5286
Willenborg D.O., Staykova M.A., and Cowden W.B. Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review. J. Neuroimmunol. 100 (1999) 21-35
Wyss-Coray T., Feng L., Masliah E., Ruppe M.D., Lee H.S., Toggas S.M., Rockenstein E.M., and Mucke L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am. J. Pathol. 147 (1995) 53-67
Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., and Mucke L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389 (1997) 603-606
Wyss-Coray T., Lin C., Sanan D.A., Mucke L., and Masliah E. Chronic overproduction of transforming growth factor-beta 1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am. J. Pathol. 156 (2000) 139-150
Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10837-10842
Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., and Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9 (2003) 453-457
Xia M.Q., and Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirology 5 (1999) 32-41
Xia M.Q., Qin S.X., Wu L.J., Mackay C.R., and Hyman B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol. 153 (1998) 31-37
Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons-regulation by synaptic activity and glucocorticoids. Neuron 11 (1993) 371-386
Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusamy P., Smith M.A., Perry G., Godman G.C., Nawroth P., et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med. 1 (1995) 693-699
Yan S.D., Stern D., Kane M.D., Kuo Y.M., Lampert H.C., and Roher A.E. RAGE-A beta interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 12 (1998) 167-173
Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., and Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23 (2003) 7504-7509
Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830 (1999) 226-236
Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154 (1999) 927-936
Yates C.M., Simpson J., Gordon A., Maloney A.F., Allison Y., Ritchie I.M., and Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 280 (1983) 119-126
Yermakova A., and O'Banion M.K. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr. Pharm. Des. 6 (2000) 1755-1776
Yermakova A.V., and O'Banion M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging 22 (2001) 823-836
Yermakova A.V., Rollins J., Callahan L.M., Rogers J., and O'Banion M.K. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol. 58 (1999) 1135-1146
Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
Zarow C., Lyness S.A., Mortimer J.A., and Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 (2003) 337-341
